Home Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
 

Keywords :   


Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

2014-11-24 14:00:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Language: English Contact: MerckMedia:Pam Eisele267-305-3558orKim Hamilton908-740-1863 / 908-391-0131orInvestors:Justin Holko908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for type application medical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11 EVA 6
23.11 8
23.11SEVENTEEN ALWAYS YOURS Weverse 13
23.11 DX
23.11 No.23/1998
23.11 DVD 9
23.11
23.11 CD His Melody
More »